214 related articles for article (PubMed ID: 32990551)
1. A Rapid and Specific HPLC Method to Determine Chemical and Radiochemical Purity of [
Migliari S; Sammartano A; Scarlattei M; Baldari G; Silva C; Ruffini L
Curr Radiopharm; 2021; 14(2):121-130. PubMed ID: 32990551
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [
Migliari S; Sammartano A; Boss M; Gotthardt M; Scarlattei M; Baldari G; Silva C; Bonadonna RC; Ruffini L
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056858
[No Abstract] [Full Text] [Related]
3. A Specific HPLC Method to Determine Residual HEPES in [
Migliari S; Scarlattei M; Baldari G; Silva C; Ruffini L
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889351
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of a High-Pressure Liquid Chromatography Method for the Determination of Chemical Purity and Radiochemical Purity of a [
Migliari S; Sammartano A; Scarlattei M; Serreli G; Ghetti C; Cidda C; Baldari G; Ortenzia O; Ruffini L
ACS Omega; 2017 Oct; 2(10):7120-7126. PubMed ID: 29520394
[No Abstract] [Full Text] [Related]
5. [
Lapa C; Schreder M; Schirbel A; Samnick S; Kortüm KM; Herrmann K; Kropf S; Einsele H; Buck AK; Wester HJ; Knop S; Lückerath K
Theranostics; 2017; 7(1):205-212. PubMed ID: 28042328
[TBL] [Abstract][Full Text] [Related]
6. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, validation and quality controls of [68Ga]-DOTA-Pentixafor for PET imaging of chemokine receptor CXCR4 expression.
Sammartano A; Migliari S; Scarlattei M; Baldari G; Ruffini L
Acta Biomed; 2020 Jul; 91(4):e2020097. PubMed ID: 33525262
[TBL] [Abstract][Full Text] [Related]
8. (68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma.
Lapa C; Lückerath K; Kleinlein I; Monoranu CM; Linsenmann T; Kessler AF; Rudelius M; Kropf S; Buck AK; Ernestus RI; Wester HJ; Löhr M; Herrmann K
Theranostics; 2016; 6(3):428-34. PubMed ID: 26909116
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor.
Herrmann K; Lapa C; Wester HJ; Schottelius M; Schiepers C; Eberlein U; Bluemel C; Keller U; Knop S; Kropf S; Schirbel A; Buck AK; Lassmann M
J Nucl Med; 2015 Mar; 56(3):410-6. PubMed ID: 25698782
[TBL] [Abstract][Full Text] [Related]
10. Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.
Bluemel C; Hahner S; Heinze B; Fassnacht M; Kroiss M; Bley TA; Wester HJ; Kropf S; Lapa C; Schirbel A; Buck AK; Herrmann K
Clin Nucl Med; 2017 Jan; 42(1):e29-e34. PubMed ID: 27819856
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, Screening, and Evaluation of Theranostic Molecular CPCR4-Based Probe Targeting CXCR4.
Yang T; Shi D; Lin Q; Shen H; Tan H; Liu Y; Shi H; Cheng D
Mol Pharm; 2024 May; 21(5):2415-2424. PubMed ID: 38606663
[TBL] [Abstract][Full Text] [Related]
12. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
[TBL] [Abstract][Full Text] [Related]
13. CXCR4 PET imaging of mantle cell lymphoma using [
Mayerhoefer ME; Raderer M; Lamm W; Pichler V; Pfaff S; Weber M; Kiesewetter B; Hacker M; Kazianka L; Staber PB; Wester HJ; Rohrbeck J; Simonitsch-Klupp I; Haug A
Theranostics; 2021; 11(2):567-578. PubMed ID: 33391493
[TBL] [Abstract][Full Text] [Related]
14. [
Watts A; Singh B; Singh H; Bal A; Kaur H; Dhanota N; Arora SK; Mittal BR; Behera D
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1216-1227. PubMed ID: 36482077
[TBL] [Abstract][Full Text] [Related]
15. Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [
Haug AR; Leisser A; Wadsak W; Mitterhauser M; Pfaff S; Kropf S; Wester HJ; Hacker M; Hartenbach M; Kiesewetter-Wiederkehr B; Raderer M; Mayerhoefer ME
Theranostics; 2019; 9(12):3653-3658. PubMed ID: 31281504
[TBL] [Abstract][Full Text] [Related]
16. Imaging Inflammation in Atherosclerosis with CXCR4-Directed
Kircher M; Tran-Gia J; Kemmer L; Zhang X; Schirbel A; Werner RA; Buck AK; Wester HJ; Hacker M; Lapa C; Li X
J Nucl Med; 2020 May; 61(5):751-756. PubMed ID: 31653710
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo - a comparison to [(68)Ga]pentixafor.
Poschenrieder A; Schottelius M; Schwaiger M; Wester HJ
EJNMMI Res; 2016 Dec; 6(1):70. PubMed ID: 27655427
[TBL] [Abstract][Full Text] [Related]
18. CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [
Jacobs SM; Wesseling P; de Keizer B; Tolboom N; Ververs FFT; Krijger GC; Westerman BA; Snijders TJ; Robe PA; van der Kolk AG
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):481-491. PubMed ID: 33550492
[TBL] [Abstract][Full Text] [Related]
19. CXCR4-Directed PET/CT with [
Chen Z; Yang A; Zhang J; Chen A; Zhang Y; Huang C; Chen S; Yao S; Miao W
Mol Imaging Biol; 2022 Jun; 24(3):416-424. PubMed ID: 34651291
[TBL] [Abstract][Full Text] [Related]
20. [68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques.
Li X; Heber D; Leike T; Beitzke D; Lu X; Zhang X; Wei Y; Mitterhauser M; Wadsak W; Kropf S; Wester HJ; Loewe C; Hacker M; Haug AR
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):558-566. PubMed ID: 28932900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]